These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37598025)

  • 21. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVID-19 vaccine safety in Scotland - background rates of adverse events of special interest.
    Cullen LA; Grange Z; Antal K; Waugh L; Alsina MS; Gibbons CL; MacDonald LE; Robertson C; Cameron JC; Stockton D; O'Leary MC
    Public Health; 2023 Nov; 224():1-7. PubMed ID: 37688806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effectiveness of vaccination for preventing hospitalisation with COVID-19 in regional Queensland: a data linkage study.
    Smoll NR; Al Imam MH; Shulz C; Booy R; Khandaker G
    Med J Aust; 2023 Aug; 219(4):162-165. PubMed ID: 37400415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
    Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
    Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COVID-19 vaccine coverage and factors associated with vaccine uptake among 23 247 adults with a recent history of homelessness in Ontario, Canada: a population-based cohort study.
    Shariff SZ; Richard L; Hwang SW; Kwong JC; Forchuk C; Dosani N; Booth R
    Lancet Public Health; 2022 Apr; 7(4):e366-e377. PubMed ID: 35278362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study.
    Florentino PTV; Millington T; Cerqueira-Silva T; Robertson C; de Araújo Oliveira V; Júnior JBS; Alves FJO; Penna GO; Vital Katikireddi S; Boaventura VS; Werneck GL; Pearce N; McCowan C; Sullivan C; Agrawal U; Grange Z; Ritchie LD; Simpson CR; Sheikh A; Barreto ML; Rudan I; Barral-Netto M; Paixão ES
    Lancet Infect Dis; 2022 Nov; 22(11):1577-1586. PubMed ID: 35952702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months.
    Low EV; Tok PSK; Husin M; Suah JL; Tng BH; Thevananthan T; Appannan MR; Yahaya H; Mohd Zin S; Muhamad Zin F; Sivasampu S; Peariasamy KM
    JAMA Netw Open; 2022 Aug; 5(8):e2226046. PubMed ID: 35947381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19 vaccination among young people who use drugs in Vancouver, Canada.
    McAdam E; Hayashi K; Barker B; Reddon H; Choi J; Kerr T; DeBeck K
    Vaccine; 2024 Feb; 42(4):864-870. PubMed ID: 38225183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19 vaccine hesitancy among people living with HIV in a low-resource setting: A multi-center study of prevalence, correlates and reasons.
    Kabir Sulaiman S; Sale Musa M; Isma'il Tsiga-Ahmed F; Muhammad Dayyab F; Kabir Sulaiman A; Dabo B; Idris Ahmad S; Abubakar Haruna S; Abdurrahman Zubair A; Hussein A; Usman S; Usman Wada J; Yekeen Ayodele A; Wulgo Ali M; Tijjani Makama B; Tijjani Bako A;
    Vaccine; 2023 Apr; 41(15):2476-2484. PubMed ID: 36932032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19 infection and vaccination uptake in men and gender-diverse people who have sex with men in the UK: analyses of a large, online community cross-sectional survey (RiiSH-COVID) undertaken November-December 2021.
    Ogaz D; Allen H; Reid D; Brown JRG; Howarth AR; Pulford CV; Mercer CH; Saunders J; Hughes G; Mohammed H
    BMC Public Health; 2023 May; 23(1):829. PubMed ID: 37147609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals.
    Vo AD; La J; Wu JT; Strymish JM; Ronan M; Brophy M; Do NV; Branch-Elliman W; Fillmore NR; Monach PA
    JAMA Netw Open; 2022 Oct; 5(10):e2240037. PubMed ID: 36264571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Undervaccination and severe COVID-19 outcomes: meta-analysis of national cohort studies in England, Northern Ireland, Scotland, and Wales.
    HDR UK COALESCE Consortium
    Lancet; 2024 Feb; 403(10426):554-566. PubMed ID: 38237625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring COVID-19 vaccine uptake and hesitancy among vulnerable populations in inner city Vancouver, Canada: Insights into characteristics and clinical outcomes.
    Beitari S; Yi S; Sharma S; Yung R; Conway B
    Vaccine; 2024 Sep; 42(22):125904. PubMed ID: 38637213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Racial/Ethnic Differences in COVID-19 Vaccine Hesitancy Among Health Care Workers in 2 Large Academic Hospitals.
    Momplaisir FM; Kuter BJ; Ghadimi F; Browne S; Nkwihoreze H; Feemster KA; Frank I; Faig W; Shen AK; Offit PA; Green-McKenzie J
    JAMA Netw Open; 2021 Aug; 4(8):e2121931. PubMed ID: 34459907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Covid-19 third vaccination during pregnancy: maternal and neonatal outcomes-a retrospective study.
    Rottenstreich M; Rotem R; Wiener-Well Y; Grisaru-Granovsky S; Sela HY
    Arch Gynecol Obstet; 2023 Oct; 308(4):1197-1205. PubMed ID: 36155854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
    Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uptake of COVID-19 vaccines and association with hospitalisation due to COVID-19 in pregnancy: Retrospective cohort study.
    Ihenetu G; Aylin P; Novov V; Skirrow H; Saxena S; Majeed A; Woodcock T
    Vaccine; 2024 Nov; 42(25):126214. PubMed ID: 39142904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Attitudes Toward COVID-19 Illness and COVID-19 Vaccination among Pregnant Women: A Cross-Sectional Multicenter Study during August-December 2020.
    Battarbee AN; Stockwell MS; Varner M; Newes-Adeyi G; Daugherty M; Gyamfi-Bannerman C; Tita AT; Vorwaller K; Vargas C; Subramaniam A; Reichle L; Galang RR; Powers E; Lucca-Susana M; Parks M; Chen TJ; Razzaghi H; Dawood FS
    Am J Perinatol; 2022 Jan; 39(1):75-83. PubMed ID: 34598291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.